BIOMEA FUSION INC. - COMMON STOCK

Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold

06 6 2024 15:05:53 提供 Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

03 6 2024 15:05:29 提供 Nasdaq GlobeNewswire

Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

30 5 2024 08:12:39 提供 Nasdaq GlobeNewswire

Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

02 5 2024 15:05:01 提供 Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 5 2024 15:10:28 提供 Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 4 2024 15:10:59 提供 Nasdaq GlobeNewswire

Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219

01 4 2024 08:02:04 提供 Nasdaq GlobeNewswire

Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

01 4 2024 08:00:11 提供 Nasdaq GlobeNewswire

Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

06 3 2024 02:04:51 提供 Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 3 2024 15:16:34 提供 Nasdaq GlobeNewswire

Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference

09 1 2024 10:02:26 提供 Nasdaq GlobeNewswire

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219

08 1 2024 08:00:26 提供 Nasdaq GlobeNewswire

Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 1 2024 15:05:00 提供 Nasdaq GlobeNewswire

Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH Annual Meeting

11 12 2023 08:25:04 提供 Nasdaq GlobeNewswire

Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts

09 12 2023 16:30:16 提供 Nasdaq GlobeNewswire

Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

08 12 2023 08:00:00 提供 Nasdaq GlobeNewswire

Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

07 12 2023 08:15:10 提供 Nasdaq GlobeNewswire

Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes

05 12 2023 07:30:23 提供 Nasdaq GlobeNewswire

Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024

27 11 2023 07:30:27 提供 Nasdaq GlobeNewswire

Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease

16 11 2023 07:30:59 提供 Nasdaq GlobeNewswire